BIONOTE, continues expansion into global markets through 'Vcheck M10'

 DISCLAIMER: This news article is a direct translation of the original Korean article from Medipana News. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BIONOTE Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.​BIONOTE announced on the 11th that they are in the process of expanding further into the global market through their Point of Care Molecular Diagnostic Analyzer, 'Vcheck M10' ("M10").M10 is an automatic analyzer that can perform both nucleic acid extraction and PCR, which previously needed to be performed separately using two different machines. The test procedure is simple enough for any veterinarians to perform on-site at the animal hospitals without separate prior training. The user can receive accurate PCR results through the M10 within an hour and removes the need to send samples to specialized labs to receive results, which can take up to 3 days.Furthermore, depending on the user's needs, they are able to customize how many channels they would like to use, up to a maximum of 8, making the M10 suitable for small hospitals, large hospitals and even labs.A BIONOTE Spokesperson commented that "The 'Canine Vector 8 Panel' recently released for the M10, has been received extremely well overseas with exponentially increasing sales numbers." and that "New sales have been recorded in countries such as Australia, Hong Kong and Mexico, with multiple European Countries in line to join the list soon as well."In addition, BIONOTE is aiming to develop and launch its 'Vcheck M Diarrhea 8 Panel' within the year, while also moving forward with international clinical evaluations in order to prove the excellence of their technology. Beyond that, they are also planning to expand into the livestock animal market through developing new tests for the M10 and expanding their catalog.Dr. Byung Ki Cho, CEO of BIONOTE, stated "It is our goal to rapidly increase our global market presence and grab hold of the veterinary POC PCR market by 2025 through our various test items" and that "Along with our new POC clinical chemistry analyzer 'Vcheck C', we will be able to lead the global market in providing total diagnostic solutions."Link to original article: https://www.medipana.com/article/view.php?news_idx=310544&sch_cate=F

• 2023.04.11
• Hits : 4,233

Bionote launches new Equine panels, eProgesterone and eSAA

Bionote, a leading veterinary diagnostic company based in Korea, is introducing two new biomarkers, eProgesterone and eSAA, as a part of the Vcheck series.    Vcheck eProgesterone is an in vitro diagnostic test kit for the quantitative measurement of progesterone concentration in Equine serum and plasma. This test kit precisely quantifies the degree of elevation in progesterone levels in horses.    Progesterone plays a crucial role in the maintenance of pregnancy until 120 days of gestation when the placenta becomes the main source. In addition, measuring progesterone helps find out mare’s reproductive cycle and plan most effectively. Vcheck eProgesterone assay allows you to quickly analyze Equine progesterone in the field, evaluate corpus callosum in the early stages of pregnancy, and monitor progesterone during pregnancy. Vcheck eProgesterone: This one-step test procedure is easy to follow and provides fast results within 15 minutes using serum and plasma samples from horses.   Vcheck Equine SAA is an in vitro diagnostic test kit for the quantitative measurement of SAA concentration in Equine serum and plasma. This test kit precisely quantifies the degree of elevation in SAA levels in horses.   SAA concentration increases in response to several clinical conditions in horses, such as sepsis, viral infections, arthritis, gastrointestinal and reproductive disease. Also, its measurement is useful for monitoring the response to treatment. Vcheck Equine SAA assay allows early detection of the presence of inflammation, monitors the post-operative effects and recovery, and serial monitoring of the response to treatment. Vcheck Equine SAA: This one-step test procedure is easy to follow and provides fast results within 5 minutes using serum and plasma samples from horses.   Bionote will also be introducing Vcheck Foal IgG within the first half of 2023. If you are interested in Vcheck eProgesterone and/or Vcheck Equine SAA, please contact your local distributor or mail to [bionote@bionote.co.kr].  

• 2023.03.27
• Hits : 2,233

Bionote Redoubles Efforts to Expand Further into the US Market

 DISCLAIMER: This news article is a direct translation of the original Korean article from Pharm News. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.- ​Bionote USA attends 'WVC 2023', the largest veterinary conference held in the US- ​Focus on Veterinary Diagnostic Analyzers such as Vcheck F and Vcheck MLeading global biological raw material and animal diagnostics company BIONOTE is continuing its efforts to expand further into the US market.Bionote announced on the 28th, that its US Branch, BIONOTE USA (established in 2019), participated in the 'Western Veterinary Conference 2023' ("WVC") held in Las Vegas, NV, from the 19th of February to the 22nd of February and carried out extensive promotional and marketing activities.WVC is the largest veterinary conference, in terms of scale, held in the US and veterinary experts as well as companies from around the world meet to share their insight, latest innovations in animal related products/services.According to Bionote, their US counterpart actively promoted their Vcheck F immunodiagnostic analyzers (V200, V2400), as well as the newly developed equine progesterone, SAA and IgG biomarkers, at the event.Furthermore, BIONOTE USA also promoted the newly released POC molecular diagnostic analyzer, Vcheck M, which is capable of nucleic acid amplification and quantitative analysis for the detection and diagnosis of major infectious diseases. Vcheck M is intuitive to use, even without much training, for performing PCR on site with the results being ready within only 1 hour, explained Bionote.A Bionote spokesperson said, "We plan on continuing our marketing and promotional activities in future conferences and events" and that "Bionote will continue to expand our market share by introducing our molecular diagnostic products and clinical chemistry products along with our usual immunodiagnostic products, showcasing our diverse product portfolio to the global market".Link to original article: https://www.pharmnews.com/news/articleView.html?idxno=219272

• 2023.03.02
• Hits : 100,927